For how we live.
Against 304 carbapenem-resistant A. baumannii isolates from six countries, the experimental drug zosurabalpin kept low MICs — including against metallo-beta-lactamase producers. This is laboratory data, not a cure.
A bird-flu virus from British Columbia poultry carried the H275Y mutation that blunts Tamiflu and peramivir. In the lab it stayed vulnerable to zanamivir and baloxavir — and was less virulent in mice.
A Manaus trial found chloroquine alone let 27% of Plasmodium vivax patients relapse by day 42; dihydroartemisinin-piperaquine cut that to 2.4%. Paired with primaquine, both drugs did well.
Across 41 hospitals in 19 Asian countries, ACORN-HAI found 73.7% of severe bloodstream and ventilator infections were drug-resistant, and 37.7% of those patients died within 28 days.
A cluster-randomised trial in Saponé found seasonal chemoprevention given to children up to age 10 nearly halved parasite carriage in 5-to-9-year-olds, though supervised delivery brought no clear gain under age five.
The AVENIR trial met its resistance endpoint in the gut but not the nose: giving the antibiotic to under-fives lifted macrolide resistance 16% above placebo communities.
In a controlled human infection trial, high-dose mosnodenvir suppressed DENV-3 far below placebo. Resistance-associated changes appeared in every sequenced recipient and none of the placebo group.